Antibody Drug Conjugates Market: Industry Expert View on Future Growth and Market Trends
The growth of antibody drug conjugates market is attributed to driving factors, such as the growing strategic partnerships to develop of antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas the high cost of ADCs development and commercialization is hindering market growth. Several companies operating in the market are taking strategic initiatives, such as enhancing product offerings with advanced technologies. For instance, in August 2023, ADC Therapeutics SA announced that two ZYNLONTA (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). The data show signs of durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Such strategic decisions are expected to enhance product and technology development by the companies and contribute significantly to market growth. The antibody drug conjugates mark...